TNFRSF9 and non-small cell lung carcinoma: One phase I study in 20 NSCLC and ten melanoma patients pretreated with ICIs evaluated the efficacy of the combination of two antibodies directed to two different receptors of the TNF family, OX-40 and CD137, with an ORR of 5% and a DCR of 40% in the NSCLC cohort (63).